Mitaka Chieko, Kudo Toshifumi, Jibiki Masatoshi, Sugano Norihide, Inoue Yoshinori, Makita Koshi, Imai Takasuke
Department of Critical Care Medicine, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
Crit Care Med. 2008 Mar;36(3):745-51. doi: 10.1097/CCM.0B013E3181659118.
Ischemia-reperfusion injury is an important cause of renal dysfunction after abdominal aortic aneurysm repair. Human atrial natriuretic peptide (hANP) is a potent endogenous natriuretic, diuretic, and vasorelaxant peptide. The objective of the present study was to evaluate the effects of hANP on renal function in patients undergoing abdominal aortic aneurysm repair.
A prospective, randomized, placebo-controlled study
Intensive care unit of a university hospital.
Forty patients undergoing elective abdominal aortic aneurysm repair.
The patients were randomized to receive a continuous infusion of either hANP (0.01-0.05 microg/kg/min) (n = 20) or placebo (n = 20) immediately before aortic cross-clamping. The infusion of hANP or placebo continued for 48 hrs.
Blood and urine samples were taken before surgery, at admission to the intensive care unit, and on days 1, 2, and 3 postoperatively, for measurement of serum concentrations of sodium, creatinine, and blood urea nitrogen and plasma concentrations of ANP and brain natriuretic peptide (BNP). Urine volume and urinary concentrations of N-acetyl-beta-D-glucosaminidase (NAG), sodium, and creatinine were also measured. The mean plasma concentration of ANP was significantly higher in the hANP group than in the placebo group. The mean plasma BNP concentration was significantly lower in the hANP group than in the placebo group. The mean serum concentrations of creatinine and blood urea nitrogen were significantly (p < .05) lower in the hANP group than in the placebo group. The mean urine volume and mean creatinine clearance were significantly (p < .05) higher in the hANP group than in the placebo group. The mean urinary NAG/creatinine ratio was significantly (p < .05) lower in the hANP group than in the placebo group.
The intraoperative and postoperative infusion of low-dose hANP preserved renal function in patients undergoing abdominal aortic aneurysm repair. Further studies are needed to assess the efficacy of prophylactic hANP infusion on perioperative renal outcome.
缺血再灌注损伤是腹主动脉瘤修复术后肾功能障碍的重要原因。人心房利钠肽(hANP)是一种强效的内源性利钠、利尿和血管舒张肽。本研究的目的是评估hANP对接受腹主动脉瘤修复术患者肾功能的影响。
一项前瞻性、随机、安慰剂对照研究
大学医院重症监护病房。
40例接受择期腹主动脉瘤修复术的患者。
患者在主动脉交叉钳夹前随机接受hANP(0.01 - 0.05微克/千克/分钟)持续输注(n = 20)或安慰剂(n = 20)。hANP或安慰剂输注持续48小时。
在手术前、重症监护病房入院时以及术后第1、2和3天采集血液和尿液样本,用于测量血清钠、肌酐和血尿素氮浓度以及血浆ANP和脑利钠肽(BNP)浓度。还测量尿量以及尿中N - 乙酰 - β - D - 氨基葡萄糖苷酶(NAG)、钠和肌酐的浓度。hANP组的平均血浆ANP浓度显著高于安慰剂组。hANP组的平均血浆BNP浓度显著低于安慰剂组。hANP组的平均血清肌酐和血尿素氮浓度显著低于安慰剂组(p < 0.05)。hANP组的平均尿量和平均肌酐清除率显著高于安慰剂组(p < 0.05)。hANP组的平均尿NAG/肌酐比值显著低于安慰剂组(p < 0.05)。
在接受腹主动脉瘤修复术的患者中,术中和术后输注低剂量hANP可保护肾功能。需要进一步研究评估预防性输注hANP对围手术期肾脏结局的疗效。